Siga Technologies
Commercial‑stage U.S. pharma SIGA Technologies, based in New York, delivers TPOXX, an oral antiviral for smallpox, targeting the health‑security market. Its biothreat focus and partnership with Cipla position it for growth in global infectious‑disease defense.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Manufacturing
- Industry: Pharmaceutical Manufacturing
- Employees: 46
- HQ: New York
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.